| Trial ID: | L0961 |
| Source ID: | NCT00223548
|
| Associated Drug: |
Sodium 2-Mercaptoethane Sulfonate
|
| Title: |
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Insufficiency|Serum Creatinine Concentration|Contrast Media Exposition
|
| Interventions: |
DRUG: sodium 2-mercaptoethane sulfonate
|
| Outcome Measures: |
Primary: Contrast-agent associated nephrotoxicity was defined as an increase in serum creatinine concentration >0.5 mg/dl (44 umol/l) of the baseline value 48 h after administration of the contrast media. | Secondary: Need for dialysis after the administration of contrast media.
|
| Sponsor/Collaborators: |
Sponsor: University of Ulm
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
106
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION
|
| Start Date: |
2002-10
|
| Completion Date: |
2004-12
|
| Results First Posted: |
|
| Last Update Posted: |
2005-09-22
|
| Locations: |
Division of Nephrology, University of Ulm, Ulm, 89081, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00223548
|
